Clinical Trial Update: A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects [Phase 1]

View source ↗

Summary

Phase I trial evaluating safety, tolerability, and pharmacokinetics of CU-40101 Liniment in adult male androgenetic alopecia subjects has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgenetic Alopecia

Drugs mentioned

• CU-40101 Liniment

Snippet

Sponsor: Cutia Therapeutics（Wuxi）Co.,Ltd | Conditions: AGA | Phase 1 | Status: COMPLETED